Maravai LifeSciences(MRVI) Prnewswire·2025-03-21 09:45Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. due to alleged securities fraud affecting investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the Company's business and prospects [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]